Aimei Health Technology Co Ltd
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30,2024
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number:001-41880
(Exact name of registrant as specified in its charter)
| Cayman Islands | N/A |
|---|---|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
10 East 53rd Street, Suite 3001
New York, NY 10022
(Address of principal executive offices) (Zip Code)
**+34 678 035200 **
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Ordinary Shares, par value $0.0001 per share | AFJK | The Nasdaq Stock Market LLC |
| Rights, exchangeable into one-fifth of one Ordinary Share | AFJKR | The Nasdaq Stock Market LLC |
| Units, each consisting of one Ordinary Share and one Right | AFJKU | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
|---|---|---|---|
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☒ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☒ No ☐
As of August 8, 2024, there were 9,026,000 ordinary shares of the Company issued and outstanding.
Aimei Health Technology Co., Ltd
Form 10-Q
For the Quarterly Period Ended June 30, 2024
Contents
| Part I | Financial Information | 1 |
|---|---|---|
| Item 1 | Financial Statements | 1 |
| Unaudited Balance Sheets as of June 30, 2024 and December 31, 2023 | 1 | |
| Unaudited Statement of Operations for the three and six months ended June 30, 2024 and for the period from April 27, 2023 (inception) through June 30, 2023 | 2 | |
| Unaudited Statement of Changes in Shareholders’ Deficit for the three and six months ended June 30, 2024 and for the period from April 27, 2023 (inception) through June 30, 2023 | 3 | |
| Unaudited Statement of Cash Flows for the six months ended June 30, 2024 and for the period from April 27, 2023 (inception) through June 30, 2023 | 4 | |
| Notes to Unaudited Financial Statements | 5 | |
| Item 2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 16 |
| Item 3 | Quantitative and Qualitative Disclosures about Market Risk | 18 |
| Item 4 | Controls and Procedures | 18 |
| Part II | Other Information | 19 |
| Item 1 | Legal Proceedings | 19 |
| Item 1A | Risk Factors | 19 |
| Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 19 |
| Item 3 | Defaults Upon Senior Securities | 19 |
| Item 4 | Mine Safety Disclosures | 20 |
| Item 5 | Other Information | 20 |
| Item 6 | Exhibits | 20 |
| Signature | 21 |
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.